Overview

PlumeStars was established in September 2013 out of a patented technology claiming the molecular deposition of fatty acids on drug microparticles to improve their aerodynamic behavior in view of the aerosol administration. In particular, the company focuses on the development of antibiotics to treat lung infections in patients affected by Cystic Fibrosis. Recently, PlumeStars aquired the capability to develop novel orphan medicines. Pharmaceutical technologies applied to different APIs for innovative medicines with primary interest in inhalation. Amikacin & Tobramycin powders for inhalations in cystic fibrosis, Cisplatin films for local delivery in mesothelioma recurrences, Thalidomide powder for oral and nasal delivery in Hereditary Haemoragic Telengiectasia, are EMA and FDA designed orphan medicines assigned to PlumeStars. PlumeStars in collaboration with the University of Parma and Interdipartmental Center for Innovation in Health Products Biopharmanet organizes research courses for doctoral students and business company. PlumeStars program consists of workshop, seminars, and courses in research skills. Subject courses deal with the technological pharmaceutical research fields and the bases of these. Specialized courses focus on the development of orphan medicines antibiotics for inhalation, implantable chemioterapic, oral and nasal drugs.